Clinical Trials Roundup

This month, we’re spotlighting five clinical trials, spanning three active areas of CRC research: immunotherapy for MSS disease, ctDNA-guided strategies after surgery, and targeted approaches for liver metastases. These summaries are written for patients, caregivers, and research advocates to help start informed conversations with your care team. 

Need help understanding clinical trials or biomarker testing? See our resources — or ask ChatCRC, Fight CRC’s AI tool, to help make sense of your biomarker report or find trials matched to your diagnosis.

September 2026

1. Denikitug (GS-1811) Alone or in Combination: A New TIGIT-Targeting Approach for MSS Colorectal Cancer 

Biomarker Focus: Microsatellite stable (MSS) / proficient mismatch repair (pMMR) metastatic CRC 
Phase / Sites: Phase II / 14 sites including Yale, Dana-Farber, Beth Israel Deaconess, Washington University, University of Virginia, Avera Cancer Institute (U.S.) and Australia 
Stage: Advanced, unresectable, or metastatic CRC; up to 2 prior lines of therapy 
Recruitment Status: Recruiting 
What It’s Studying: This Phase II trial evaluates denikitug (GS-1811), a Gilead-sponsored investigational antibody targeting TIGIT, an immune checkpoint that helps tumors evade the immune system. The study tests denikitug alone, combined with nivolumab (anti-PD-1), and combined with trifluridine-tipiracil plus bevacizumab in MSS metastatic CRC patients who have received up to two prior lines of therapy. 
Why It Matters: MSS colorectal cancer accounts for roughly 85–90% of all metastatic cases and has largely been excluded from the immunotherapy advances seen in MSI-H/dMMR disease. TIGIT is a distinct checkpoint target, separate from PD-1 and CTLA-4, and blocking it may help unlock immune responses in tumors that currently resist checkpoint therapy. This is the first Phase II TIGIT-targeting trial specifically designed for MSS CRC with multiple combination arms, representing a genuinely new research direction for the largest group of patients who lack immunotherapy options today. 
Patient Tip: If your tumor is MSS or pMMR and you’ve received one or two prior chemotherapy regimens, ask your oncologist: ‘Are there trials targeting TIGIT or other new immune checkpoints that I might qualify for?’ MSS does not mean immunotherapy is off the table; it means the approach needs to be different, and trials like this one are building that path. 
Provider Tip: If you’ve received one or two prior chemotherapy regimens and your tumor is MSS, you may be eligible for this trial — but timing matters. Make sure your care team knows your full treatment history, including whether you’ve received trifluridine-tipiracil, regorafenib, or fruquintinib, as these can affect which arm of the study you qualify for. Sites at major cancer centers including Dana-Farber and Washington University may be worth asking about if travel is an option. 
ClinicalTrials.gov: NCT07527858

2. Balstilimab + Botensilimab + agenT-797: Combining Cell Therapy and Immunotherapy for MSS CRC With Liver Metastases 

Biomarker Focus: MSS / pMMR metastatic CRC with liver metastases 
Phase / Sites: Phase II / 1 U.S. site: Scripps Clinic Torrey Pines, La Jolla, California 
Stage: Metastatic CRC with liver involvement; ≥1 prior line including fluorouracil, oxaliplatin, and irinotecan 
Recruitment Status: Recruiting 
What It’s Studying: This investigator-sponsored Phase II trial at Scripps Health tests a three-drug combination: balstilimab (anti-PD-1), botensilimab (Fc-enhanced anti-CTLA-4), and agenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy. The study specifically enrolls patients with MSS metastatic CRC that has spread to the liver, a population with historically lower immunotherapy response rates because the liver microenvironment actively suppresses immune activity. Patients must have at least one measurable liver lesion and no prior immunotherapy. 
Why It Matters: Three-year BOT/BAL survival data from ESMO GI 2026 generated significant interest, but that dataset largely excluded patients with active liver metastases, a common and clinically important scenario in metastatic CRC. This trial adds agenT-797, an off-the-shelf iNKT cell therapy, to the BOT/BAL backbone to ask whether cellular therapy can help break through the liver’s immune resistance. It is the first trial to combine iNKT cell therapy with dual checkpoint blockade specifically for MSS CRC with liver involvement. 
Patient Tip: If your cancer has spread to the liver and your tumor is MSS, conversations about immunotherapy may have felt discouraging. This trial is asking whether adding a cellular therapy on top of dual checkpoint blockade can change that equation. The single California site may not be accessible to everyone, but asking your oncologist about trials combining cell therapy with immunotherapy for MSS liver-involved disease may open doors to similar options.
ClinicalTrials.gov: NCT07550088

3. TAS-102 for ctDNA-Positive Minimal Residual Disease: Testing Whether Treatment Can Erase ‘Hidden’ Cancer After Surgery 

Biomarker Focus: ctDNA-positive minimal residual disease (MRD) after curative-intent surgery and adjuvant chemotherapy 
Phase / Sites: Phase II / MD Anderson Cancer Center, Houston, Texas 
Stage: Stage II, III, or IV; R0 resected, curative-intent therapy completed, ctDNA-positive with no radiographic disease 
Recruitment Status: Recruiting 
What It’s Studying: This MD Anderson Phase II trial tests whether trifluridine-tipiracil (TAS-102), an oral chemotherapy, can clear circulating tumor DNA (ctDNA) from the blood of colorectal cancer patients who have finished curative-intent surgery and at least three months of oxaliplatin-based adjuvant chemotherapy. Eligible patients must have a positive ctDNA test with no visible tumor on imaging, a state researchers call minimal residual disease (MRD). The primary goal is measuring how many patients achieve ctDNA clearance at six months. 
Why It Matters: Positive ctDNA after surgery is one of the strongest signals of recurrence risk in CRC, often detectable months before anything shows on a scan. But detecting it raises an urgent question the field hasn’t yet answered: if we find it, can we treat it? This is one of the first trials to test an active therapeutic intervention for ctDNA-positive MRD in CRC, rather than surveillance alone. A positive result could reshape post-surgical care for a high-risk group that currently has no clear treatment standard.
Patient Tip: If you have finished surgery and chemotherapy, your scans are clear, but you’ve heard about ctDNA testing, this trial speaks directly to your situation. Ask your care team: ‘Has my ctDNA been tested, and if it’s positive, are there trials designed to treat what’s left behind?’ Not all centers routinely offer ctDNA testing after surgery, so asking specifically is an important first step. 
Provider Tip: If your scans are clear after surgery and chemotherapy but a ctDNA test has come back positive, this trial may be an option worth discussing. Ask your care team whether your ctDNA result was confirmed through a CLIA-certified lab — Signatera is the preferred assay for enrollment. This trial is at MD Anderson in Houston, so it requires travel, but for patients who want to act on a positive ctDNA result rather than wait, it’s a conversation worth having.
ClinicalTrials.gov: NCT05343013

4. Adjuvant Toripalimab: Immunotherapy After Surgery for High-Risk dMMR/MSI-H Colon Cancer 

Biomarker Focus: Deficient mismatch repair (dMMR) / MSI-H; Stage IIB, IIC, or III colon cancer 
Phase / Sites: Phase II / 5 Emory network sites, Atlanta, Georgia (NCI-sponsored) 
Stage: Localized; Stage IIB, IIC, or III colon cancer, R0 resected 
Recruitment Status: Recruiting 
What It’s Studying: This Emory/NCI Phase II trial tests toripalimab, an anti-PD-1 immunotherapy, as a standalone adjuvant treatment for patients with high-risk dMMR/MSI-H colon cancer following complete resection. Participants receive eight doses over six months, with a primary endpoint of three-year disease-free survival. Unlike the ATOMIC trial (featured in Fight CRC’s January 2026 Roundup), which added immunotherapy to adjuvant chemotherapy, this study tests immunotherapy alone, asking whether the dMMR biology of these tumors makes a chemotherapy-free approach both effective and better tolerated. 
Why It Matters: For dMMR patients, the question of whether immunotherapy can replace — not just add to — post-surgical chemotherapy is one of the most patient-relevant open questions in CRC. Many patients in this situation are motivated to avoid chemotherapy side effects if biology supports it. This trial also tracks patient-reported outcomes alongside efficacy data, meaning results will speak to quality of life, not just survival, which matters deeply to newly operated patients weighing their next step.
Patient Tip: If you’ve just had surgery for Stage IIB, IIC, or III colon cancer and your tumor is MSI-H or dMMR, you may be in an enrollment window for this trial. The window is narrow: four to twelve weeks after surgery — so the conversation needs to happen soon. Ask your care team before starting adjuvant chemotherapy: ‘Am I a candidate for an immunotherapy-only trial after surgery?
Provider Tip: If you’ve just had surgery for dMMR or MSI-H colon cancer, the window to enroll in this trial is four to twelve weeks post-surgery, so bring it up with your oncologist at your first post-operative visit, before any adjuvant treatment decisions are made. Make sure your pathology report confirms dMMR or MSI-H status, and let your care team know if you received any treatment before surgery, as this may affect eligibility.
ClinicalTrials.gov: NCT07140679

5. The PUMP Trial: Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Colorectal Liver Metastases 

Biomarker Focus: No specific biomarker requirement; liver-confined unresectable colorectal cancer metastases (excludes MSI-H) 
Phase / Sites: Phase III / 62 U.S. sites across ~20 states, including MSK, Mayo Clinic, Northwestern, Duke, Emory, UT Southwestern, Ohio State, Fox Chase, Vanderbilt, and more (ECOG-ACRIN / NCI-sponsored) 
Stage: Stage IV; unresectable colorectal liver metastases, liver-confined disease, after 3–6 months of first-line chemotherapy with stable or responding disease 
Recruitment Status: Recruiting 
What It’s Studying: The PUMP Trial is a randomized Phase III study comparing standard systemic chemotherapy alone against systemic chemotherapy plus hepatic arterial infusion (HAI), a surgically implanted pump that delivers floxuridine chemotherapy directly into the liver’s blood supply. Sponsored by ECOG-ACRIN and the NCI, the trial enrolls patients with colorectal cancer that has spread only to the liver and cannot be surgically removed, who have stable or responding disease after completing three to six months of first-line chemotherapy. The primary endpoint is overall survival. 
Why It Matters: HAI pump chemotherapy is FDA-approved and has shown strong results at high-volume centers like Memorial Sloan Kettering, but it remains underused nationally, largely because most patients never hear about it. By delivering chemotherapy directly into the liver’s arterial supply, HAI achieves much higher drug concentrations at the tumor site than systemic chemotherapy alone can reach. The PUMP Trial is the largest randomized effort to define whether adding HAI to modern systemic therapy can extend survival, and its 62 U.S. sites make it one of the most geographically accessible trials in this Roundup. 
Patient Tip: If your colorectal cancer has spread to the liver and your doctors have said surgery isn’t currently possible, ask specifically: ‘Am I a candidate for a hepatic arterial infusion pump, and is the PUMP Trial available near me?’ HAI is not widely offered outside of specialized centers, so many patients who could benefit simply don’t know to ask. With sites at major cancer centers across the country, access to this trial is broader than most.
Provider Tip: Key eligibility: liver-confined unresectable CRC confirmed by multidisciplinary review, stable/responding disease after 3-6 months of first-line chemotherapy, no prior HAI or FUDR, no prior liver-directed therapy (TACE, TARE), no MSI-H disease, ECOG 0–1, liver tumor burden ≤70%. CT angiography confirming acceptable hepatic arterial anatomy is required within 4 weeks of randomization. With 62 active U.S. sites, the PUMP Trial is the most geographically accessible trial in this month’s Roundup and worth a proactive referral conversation for liver-confined metastatic CRC patients. 
ClinicalTrials.gov: NCT05863195

Disclaimer: Inclusion in this roundup does not imply endorsement or guaranteed benefit. Always consult your healthcare provider to determine whether a clinical trial is appropriate for you. Recruitment status is current as of publication and subject to change. Verify current status at ClinicalTrials.gov before making any treatment decisions. 

August 2026

1. Symbiotic-GI-03 — A Clinical Trial Researching a Potential Combination Treatment for People With Metastatic Colorectal Cancer

Phase / Sites: Phase III / ~210 sites worldwide
Stage: Stage IV metastatic colorectal adenocarcinoma
Recruitment Status: Recruiting
What it’s studying: Pfizer’s Phase 3 double-blind clinical trial is evaluating a potential first-line treatment for patients with metastatic colorectal cancer who have not received prior anticancer treatment for metastatic disease. The study medicine, PF-08634404, is an investigational bispecific antibody that targets both PD-1 (an immune checkpoint) and VEGF (a protein that supports tumor blood vessel growth) at the same time. It is thought that by binding to these proteins, the study medicine may help the immune system find and attack the cancer cells while also potentially slowing tumor growth. Participants will receive either the study medicine in combination with chemotherapy, or bevacizumab, in combination with chemotherapy.
Why it matters: Bevacizumab combined with chemotherapy remains a common first-line standard treatment for colorectal cancer, but outcomes are still limited. Most colorectal cancers, especially those that are not MSI-H/dMMR, do not respond to immunotherapy alone. This clinical trial is researching whether the study medicine combination may improve progression-free survival (PFS) and overall survival (OS) compared to the bevacizumab combination.
Patient Tip: If you are diagnosed with metastatic colorectal cancer and have not yet started treatment, ask your doctor whether a first-line clinical trial such as Symbiotic-GI-03 may be an option for you. It is recommended that your tumor has been tested for key biomarkers, including RAS, BRAF V600E, and MSI/dMMR, as these results may help determine your eligibility for this clinical trial and others. 
ClinicalTrials.gov: NCT07222800  |  www.PfizerStudyforCRC.com 

2. INCA033890-303 — Chemotherapy + Bevacizumab With or Without INCA33890 in First-Line MSS Metastatic CRC 

Biomarker Focus: Microsatellite stable (MSS) / mismatch repair proficient (pMMR) metastatic CRC; excludes MSI-H/dMMR and BRAF V600E 
Phase / Sites: Phase III / Multicenter, including U.S. sites (Incyte-sponsored) 
Stage: Stage IV metastatic colorectal adenocarcinoma, first-line 
Recruitment Status: Recruiting 
What it’s studying: INCA033890-303 is a Phase 3 randomized, double-blind study comparing standard first-line chemotherapy plus bevacizumab with or without INCA33890, an investigational bispecific antibody targeting both PD-1 and TGFβR2 (transforming growth factor beta receptor 2). The trial enrolls patients with MSS metastatic CRC who have not previously received systemic treatment for metastatic disease. 
Why it matters: MSS colorectal cancer accounts for the large majority of metastatic cases and has historically been resistant to immunotherapy. A key reason is that TGF-beta signaling in the tumor environment actively suppresses the immune response. INCA33890 is designed to address this by blocking TGFβR2 specifically on immune cells that also express PD-1, a more targeted approach than prior TGF-beta inhibitors that caused significant toxicity. Along with Symbiotic-GI-03 and HARMONi-GI3, it is one of only three Phase 3 trials currently seeking to change how MSS mCRC is treated in the first line. 
Patient Tip: MSS is the most common biomarker profile in metastatic CRC, and historically it has meant fewer immunotherapy options. If that sounds like your diagnosis, it’s worth asking your oncologist whether this trial is available near you before you begin standard treatment. The eligibility window is first-line only, so the conversation needs to happen before chemotherapy starts. 
ClinicalTrials.gov: NCT07284849 

3. ROSETTA CRC-203 — Pumitamig + Chemotherapy vs. Bevacizumab + Chemotherapy in First-Line Metastatic CRC 

Biomarker Focus: First-line mCRC without dMMR, MSI-H, or BRAF V600E (broad MSS/RAS population)
Phase / Sites: Phase II/III / Global multicenter, including U.S. sites (Bristol-Myers Squibb / BioNTech) 
Stage: Stage IV unresectable or metastatic colorectal cancer, first-line 
Recruitment Status: Recruiting 
What it’s studying: ROSETTA CRC-203 is evaluating pumitamig, an investigational bispecific antibody targeting both PD-L1 and VEGF-A, in combination with standard chemotherapy compared against bevacizumab plus chemotherapy in patients with previously untreated, unresectable or metastatic CRC without dMMR, MSI-H, or BRAF V600E. Early Phase 2 data presented at ASCO 2026 showed promising activity, and the study is now enrolling its Phase 3 registrational cohort. 
Why it matters: Pumitamig targets PD-L1 rather than PD-1, which some researchers believe may have advantages in the tumor microenvironment of MSS CRC. The ASCO 2026 interim data generated significant interest, and enrollment into the Phase 3 portion represents an early opportunity for patients to access a drug that has not yet completed its pivotal trial. 
Patient Tip: There’s a lot happening in first-line CRC research right now, and it can feel overwhelming to keep up. Here’s a simple question worth bringing to your next appointment: ‘Are there any trials testing new combinations in first-line treatment that I might qualify for?’ Asking early, before treatment begins, is the only way to know if something like ROSETTA CRC-203 is an option for you. 
ClinicalTrials.gov: NCT07221357

4. MOUNTAINEER-03 — Tucatinib + Trastuzumab + mFOLFOX6 in HER2-Positive First-Line Metastatic CRC 

Biomarker Focus: HER2-positive, RAS wild-type first-line mCRC 
Phase / Sites: Phase III / 50+ sites globally, including U.S. 
Stage: Stage IV metastatic CRC, first-line 
Recruitment Status: Recruiting 
What it’s studying: MOUNTAINEER-03 is testing whether adding tucatinib and trastuzumab, a dual HER2-targeting combination, to standard first-line chemotherapy improves outcomes for the roughly 4% of metastatic CRC patients with HER2-amplified, RAS wild-type tumors. This Phase 3 trial compares tucatinib plus trastuzumab plus mFOLFOX6 against the current standard of care. 
Why it matters: HER2-targeted therapy has already shown meaningful benefit in patients with HER2-positive CRC who have progressed on prior lines of treatment. MOUNTAINEER-03 asks whether starting HER2 targeting earlier, at the very first line of metastatic treatment, can extend those benefits further. If positive, it would establish a new first-line standard for this biomarker subgroup. 
Patient Tip: HER2 testing is not always automatically included when you’re first diagnosed. If you’ve gotten biomarker results back and aren’t sure whether HER2 was checked, ask specifically. It’s a simple question with a potentially significant answer, especially if you’re RAS wild-type. Your care team can order the test, and it takes the guesswork out of knowing which trials you might qualify for. 
ClinicalTrials.gov: NCT05253651

5. FRUITFUL — Fruquintinib + FOLFIRI as Second-Line Treatment for Metastatic CRC 

Biomarker Focus: MSS/pMMR mCRC without BRAF V600E; prior oxaliplatin, fluoropyrimidine, and bevacizumab in first line 
Phase / Sites: Phase II / 14 U.S. sites across 9 states (SCRI-sponsored) 
Stage: Stage IV metastatic CRC, second-line 
Recruitment Status: Recruiting 
What it’s studying: FRUITFUL is a Phase II study evaluating fruquintinib, an FDA-approved oral VEGFR inhibitor, in combination with FOLFIRI chemotherapy as second-line treatment for patients with metastatic CRC. Participants must have completed first-line oxaliplatin, fluoropyrimidine, and bevacizumab-based therapy. The study is testing whether adding fruquintinib to the standard second-line FOLFIRI backbone can improve outcomes for patients progressing after first-line treatment. 
Why it matters: Fruquintinib is already FDA-approved as a later-line monotherapy for mCRC, but this trial explores whether its anti-angiogenic mechanism works even better when combined with chemotherapy earlier in the treatment sequence. For patients who have finished first-line therapy and are planning their next step, this is a meaningful opportunity to access a novel combination at a critical transition point. Sites span nine states, making this one of the more geographically accessible trials currently enrolling. 
Patient Tip: If you’ve just finished first-line treatment and your cancer has progressed, this might be exactly the kind of trial worth asking about at your next appointment. The eligibility is fairly straightforward: prior oxaliplatin-based chemo plus bevacizumab, no prior irinotecan. You don’t need a specific biomarker result to qualify, which makes it one of the more accessible trials for a broader group of patients right now. 
ClinicalTrials.gov: NCT07011576

July 2026 

1. OrigAMI-1 — Amivantamab Alone or With Chemotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic CRC 

Biomarker Focus: RAS/BRAF wild-type and HER2 non-amplified metastatic CRC; tumor sidedness evaluated 
Phase / Sites: Phase Ib/II / International multicenter, including U.S. sites 
Stage: Advanced or metastatic CRC, two to three prior lines of therapy 
Recruitment Status: Active, ongoing (combination chemotherapy cohorts) 
What it’s studying: OrigAMI-1 is the foundational study evaluating amivantamab, a bispecific antibody targeting both EGFR and MET, alone or combined with mFOLFOX6 or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic CRC after two to three prior lines of therapy. 
Why it matters: Updated results at ASCO GI 2026 showed over 70% of patients in the first-line combination chemotherapy subgroup responded, with most responses lasting beyond 16 months; results that launched two pivotal phase 3 studies now enrolling (OrigAMI-2 and OrigAMI-3, below). 
Patient Tip: If you have RAS/BRAF wild-type CRC and have been through several lines of treatment, ask your care team whether early-phase trials studying newer EGFR-targeting combinations are still open to enrollment.
ClinicalTrials.gov: NCT05379595 

2. OrigAMI-2 — Amivantamab + Chemotherapy vs. Cetuximab + Chemotherapy in First-Line Left-Sided RAS/BRAF Wild-Type Metastatic CRC 

Biomarker Focus: RAS/BRAF wild-type (KRAS, NRAS, and BRAF all wild-type); left-sided primary tumor 
Phase / Sites: Phase III / Global multicenter, including U.S. sites 
Stage: Unresectable or metastatic colorectal cancer, first-line 
Recruitment Status: Recruiting 
What it’s studying: OrigAMI-2 is comparing amivantamab plus chemotherapy (mFOLFOX6 or FOLFIRI) versus cetuximab plus chemotherapy as first-line treatment for patients with left-sided, RAS/BRAF wild-type metastatic CRC. 
Why it matters: Anti-EGFR therapy with chemotherapy is already the standard for this group, but resistance develops in most patients. Data from ESMO GI 2026 showed liquid biopsy can track that resistance; OrigAMI-2 is testing whether targeting both EGFR and MET from the start delays it. 
Patient Tip: If your tumor is RAS/BRAF wild-type and left-sided, ask your care team whether there are first-line trials testing a next-generation EGFR-targeting approach before starting standard treatment. 
ClinicalTrials.gov: NCT06662786

3. OrigAMI-3 — Amivantamab + FOLFIRI vs. Cetuximab or Bevacizumab + FOLFIRI in Second-Line RAS/BRAF Wild-Type Metastatic CRC 

Biomarker Focus: RAS/BRAF wild-type (KRAS, NRAS, and BRAF all wild-type) metastatic CRC 
Phase / Sites: Phase III / Global multicenter, including U.S. sites (Fox Chase Cancer Center, UCLA, and others) 
Stage: Recurrent, unresectable, or metastatic CRC after first-line chemotherapy 
Recruitment Status: Recruiting 
What it’s studying: OrigAMI-3 is evaluating subcutaneous amivantamab plus FOLFIRI versus standard second-line treatment (cetuximab or bevacizumab plus FOLFIRI) in patients with RAS/BRAF wild-type metastatic CRC who progressed on first-line chemotherapy. 
Why it matters: MET amplification is a known mechanism by which CRC develops resistance to anti-EGFR therapy after first-line treatment; amivantamab targets both EGFR and MET, and phase 1b/2 data from ASCO GI 2026 showed promising activity even in patients with prior anti-EGFR exposure. 
Patient Tip: If you have RAS/BRAF wild-type CRC and your cancer progressed on first-line therapy, ask your care team whether a second-line trial targeting both EGFR and MET could be right for you. 
ClinicalTrials.gov: NCT06750094

4. Botensilimab + Balstilimab + Fasting Mimicking Diet + Vitamin C for KRAS-Mutant MSS Metastatic CRC 

Biomarker Focus: KRAS-mutant, microsatellite stable (MSS) metastatic colorectal cancer 
Phase / Sites: Phase Ib / University of Southern California (Los Angeles, CA) 
Stage: Metastatic colorectal cancer after prior fluoropyrimidine, oxaliplatin, and irinotecan 
Recruitment Status: Recruiting 
What it’s studying: This study evaluates botensilimab and balstilimab combined with a fasting mimicking diet (a structured, plant-based, low-calorie eating plan) and high-dose intravenous vitamin C in patients with KRAS-mutant MSS metastatic CRC. 
Why it matters: ESMO GI 2026 featured three-year survival data for botensilimab plus balstilimab in MSS CRC; this trial explores whether adding metabolic strategies can extend that benefit to patients with KRAS mutations, who make up a large share of MSS metastatic CRC cases. 
Patient Tip: If your tumor is MSS and has a KRAS mutation, ask your care team whether trials combining immunotherapy with nutritional or metabolic strategies are available to you. 
ClinicalTrials.gov: NCT06336902

 5. Botensilimab + Balstilimab + SBRT for MSS CRC With Liver Metastases 

Biomarker Focus: Non-MSI-H or mismatch repair proficient (pMMR) colorectal cancer with liver metastases 
Phase / Sites: Pilot study / Massachusetts General Hospital (Boston, MA) 
Stage: Metastatic colorectal cancer with liver metastases 
Recruitment Status: Recruiting 
What it’s studying: This study evaluates botensilimab and balstilimab combined with stereotactic body radiation therapy (SBRT) to liver metastases in patients with MSS or pMMR CRC, asking whether precisely targeted radiation can activate an immune response in a setting where immunotherapy alone has been harder to get to work. 
Why it matters: The three-year ESMO GI 2026 BOT/BAL data came from patients without active liver metastases; liver involvement is associated with lower immunotherapy response rates in MSS CRC, and this trial directly addresses that gap. 
Patient Tip: If your cancer has spread to the liver, ask your care team whether trials combining radiation with newer immunotherapy drugs are available at your treatment center. 
ClinicalTrials.gov: NCT07128355 

June 2026

1. HARMONi-GI3 — Ivonescimab + mFOLFOX6 in First-Line Metastatic Colorectal Cancer

Biomarker Focus: Metastatic colorectal cancer; immunotherapy and VEGF pathway strategy
Phase / Sites: Phase III / Multicenter
Stage: Metastatic colorectal cancer
Recruitment Status: Recruiting
What It’s Studying:
This study compares ivonescimab plus mFOLFOX6 chemotherapy with bevacizumab plus mFOLFOX6 for patients who have not yet received systemic treatment for metastatic CRC.
Why It Matters:
First treatment decisions can feel urgent and overwhelming. This trial is studying whether combining chemotherapy with a treatment that targets both immune response and tumor blood-vessel growth may offer another first-line approach.
Patient Tip:
Ask your care team: “Do I know my MSI/MMR status, and are there any first-line clinical trials that match my diagnosis and treatment goals?”
ClinicalTrials.gov: NCT07228832

2. BAY 3771249 — KRAS G12D-Targeted Therapy for Advanced or Metastatic CRC

Biomarker Focus: KRAS G12D mutation
Phase / Sites: Phase I / Multicenter
Stage: Advanced or metastatic colorectal cancer
Recruitment Status: Recruiting
What It’s Studying:
This study is evaluating BAY 3771249, an investigational treatment being studied alone or with cetuximab for patients with advanced or metastatic CRC that has a KRAS G12D mutation.
Why It Matters:
KRAS G12D has limited targeted treatment options. This trial reflects the growing effort to develop therapies based on the exact KRAS mutation driving a person’s cancer.
Patient Tip:
Ask your care team: “Do I have a KRAS G12D mutation, and are there trials designed specifically for this subtype?”
ClinicalTrials.gov: NCT07535112

3. SGN-CEACAM5C — Antibody-Drug Conjugate Targeting CEACAM5

Biomarker Focus: CEACAM5 expression
Phase / Sites: Phase I / International study with U.S. sites
Stage: Advanced solid tumors, including colorectal cancer cohorts
Recruitment Status: Recruiting
What It’s Studying:
This study is evaluating SGN-CEACAM5C, also known as PF-08046050, in adults with advanced solid tumors, including CRC cohorts. Antibody-drug conjugates are designed to deliver treatment more directly to cancer cells with a specific target.
Why It Matters:
When standard treatments stop working, patients often want to know what other options are being studied. This trial is one example of research exploring more targeted approaches for advanced CRC.
Patient Tip:
Ask your care team: “Has my tumor been tested for markers that could help match me to a targeted therapy or antibody-drug conjugate trial?”
ClinicalTrials.gov: NCT06131840

4. EMPIRE / NSABP FC-13 — Immunotherapy for ctDNA-Positive Minimal Residual Disease

Biomarker Focus: ctDNA-positive minimal residual disease after colorectal cancer treatment
Phase / Sites: Phase II / Multicenter
Stage: Colorectal cancer after definitive surgery and chemotherapy, with ctDNA positivity
Recruitment Status: Recruiting
What It’s Studying:
EMPIRE is studying cemiplimab alone or with other immunotherapy-based treatments for people with CRC who are ctDNA-positive after surgery and chemotherapy. ctDNA is tumor DNA that can sometimes be detected through a blood test.
Why It Matters:
Many patients want to know what ctDNA results may mean for recurrence risk and next steps. This study is asking whether immunotherapy-based treatment can help delay or prevent colorectal cancer from coming back in patients with ctDNA-positive minimal residual disease.
Patient Tip:
If you have completed surgery and chemotherapy, ask your care team: “Is ctDNA testing appropriate for me, and would a positive result change my follow-up plan or clinical trial options?”
ClinicalTrials.gov: NCT07058012

5. KANDLELIT-012 — Calderasib (MK-1084) + Cetuximab + mFOLFOX6 for KRAS G12C-Mutated Colorectal Cancer

Biomarker Focus: KRAS G12C mutation
Phase / Sites: Phase III / Multicenter
Stage: Locally advanced unresectable or metastatic colorectal cancer
Recruitment Status: Recruiting
What It’s Studying:
This study is evaluating calderasib, also known as MK-1084, with cetuximab and mFOLFOX6 chemotherapy compared with mFOLFOX6 with or without bevacizumab in KRAS G12C-mutated CRC.
Why It Matters:
KRAS mutations are common in CRC, but not all KRAS mutations are the same. This trial focuses on KRAS G12C and reflects the movement toward treatments matched to specific tumor biomarkers.
Patient Tip:
If your care team says your tumor has a KRAS mutation, ask: “Which KRAS mutation do I have, and does that specific result make me eligible for any clinical trials?”
ClinicalTrials.gov: NCT06997497

6. Bonus Research Watch: CRDF-004 — Onvansertib + Chemotherapy and Bevacizumab for RAS-Mutated Metastatic Colorectal Cancer

Biomarker Focus: KRAS or NRAS mutation
Phase / Sites: Phase II / U.S. multicenter study
Stage: First-line metastatic colorectal cancer
Recruitment Status: Active, not recruiting
What It’s Studying:
CRDF-004 is studying onvansertib with standard chemotherapy and bevacizumab for adults with metastatic CRC that has a KRAS or NRAS mutation.
Why It Matters:
RAS mutations are common in metastatic CRC, and researchers continue to look for better first-line strategies. This trial is not currently recruiting, but it remains important to watch because ASCO 2026 featured interim results from CRDF-004 in first-line RAS-mutated metastatic CRC.
Patient Tip:
If your tumor has a KRAS or NRAS mutation, ask your care team: “Are there current or upcoming trials for RAS-mutated colorectal cancer that may fit my treatment plan?”
ClinicalTrials.gov: NCT06106308

May 2026

1. NCI ComboMATCH — Combination Therapy Based on Tumor Genetics 

Biomarker Focus: Actionable genetic alterations 
Phase / Sites: Screening trial supporting multiple Phase II treatment sub-studies  / U.S. NCI network 
Stage: Advanced solid tumors, including colorectal cancer when biomarker eligible 
Recruitment Status: Recruiting 
What it’s studying: ComboMATCH assigns patients to treatment combinations based on tumor genetic changes rather than cancer type alone, using a screening platform that matches patients to specific sub-studies. 
Why it matters: This builds on precision medicine by testing whether targeted drug combinations can improve outcomes for patients whose tumors have actionable alterations. 
Patient Tip: If you’ve had genomic testing, ask whether your results include an alteration that could match to a precision medicine trial. 
ClinicalTrials.gov: NCT05564377 
 

2. BASECAMP-1 — Screening Study for Future CEA-Targeted Cell Therapy 

Biomarker Focus: CEA expression, HLA type (including HLA loss of heterozygosity), tumor immune markers 
Phase / Sites: Observational screening study / U.S. sites 
Stage: Solid tumors, including colorectal cancer 
Recruitment Status: Recruiting 
What it’s studying: BASECAMP-1 screens patients for biomarkers that may determine eligibility for future CEA-targeted cell therapy studies. 
Why it matters: This expands biomarker testing beyond tumor mutations to include immune matching and cell therapy eligibility. 
Patient Tip: If you’re interested in cell therapy trials, ask whether HLA typing or CEA testing could be relevant. 
ClinicalTrials.gov: NCT04981119 

3. Onvansertib Combination Trial — KRAS-Mutant Metastatic Colorectal Cancer 

Biomarker Focus: KRAS mutation 
Phase / Sites: Phase II / U.S. and international sites 
Stage: Metastatic colorectal cancer 
Recruitment Status: Active, Not Recruiting 
What it’s studying: This study evaluates onvansertib with standard chemotherapy and bevacizumab in patients with KRAS-mutant metastatic colorectal cancer. 
Why it matters: KRAS mutations are common in CRC, but many KRAS-mutant tumors still lack effective targeted options. This study focuses on a biologically defined CRC group. 
Patient Tip: If your tumor has a KRAS mutation, ask whether the specific KRAS variant and prior treatments affect trial eligibility. 
ClinicalTrials.gov: NCT06106308 
 

4. P-MUC1C-ALLO1 — Allogeneic CAR-T Cell Therapy Targeting MUC1-C 

Biomarker Focus: MUC1-C expression 
Phase / Sites: Phase I / Includes U.S. sites 
Stage: Advanced or metastatic solid tumors, including colorectal cancer 
Recruitment Status: Active, Not Recruiting 
What it’s studying: This study evaluates an allogeneic CAR-T cell therapy targeting MUC1-C, a tumor-associated marker expressed in several epithelial cancers. 
Why it matters: Cell therapy research in CRC is expanding, and biomarker testing may help identify patients whose tumors express targets like MUC1-C. 
Patient Tip: Ask whether your tumor testing includes protein-expression markers, not just DNA mutations. 
ClinicalTrials.gov: NCT05239143 

5. GCC19CART — CAR-T Therapy Targeting GCC in Advanced Gastrointestinal Cancers 

Biomarker Focus: GCC / guanylyl cyclase C expression 
Phase / Sites: Phase I / U.S. sites 
Stage: Metastatic colorectal cancer 
Recruitment Status: Recruiting 
What it’s studying: This trial evaluates CAR-T cells targeting GCC, a marker commonly associated with colorectal cancer cells. 
Why it matters: GCC-targeted cell therapy is a CRC-relevant biomarker strategy and represents a newer research direction for patients with advanced disease. 
Patient Tip: If you are exploring cell therapy options, ask whether your tumor expresses GCC or whether a GCC-targeted study is available. 
ClinicalTrials.gov: NCT05319314 

April 2026

1. JANUS Rectal Cancer Trial — Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer 
Biomarker Focus: Response-adapted treatment and organ preservation strategy 
Phase / Sites: Phase II / U.S. cooperative group, multicenter 
Stage: Stage II-III / locally advanced rectal cancer 
Recruitment Status: Active, not recruiting 
What it’s studying: JANUS is comparing long-course chemoradiation followed by mFOLFIRINOX versus mFOLFOX6 to improve clinical complete response and organ preservation in locally advanced rectal cancer. 
Why it matters: This study is relevant right now because it focuses on treatment intensification and organ-preservation goals in rectal cancer—an area of strong interest for patients and clinicians alike. 
Patient Tip: If you are discussing treatment before rectal cancer surgery, ask whether total neoadjuvant therapy or organ-preservation strategies may be appropriate for you. 
ClinicalTrials.gov: NCT05610163 

2. EA2201 — Immunotherapy in dMMR Stage II/III Rectal Cancer 
Biomarker Focus: Deficient mismatch repair (dMMR) / MSI-H 
Phase / Sites: Phase II / Multicenter U.S. trial 
Stage: Stage II–III locally advanced rectal adenocarcinoma 
Recruitment Status: Active, not recruiting 
What it’s studying: EA2201 is evaluating nivolumab + ipilimumab with short-course radiation in patients with MSI-H/dMMR rectal cancer, with the goal of improving response while potentially reducing the need for more intensive conventional treatment. 
Why it matters: dMMR rectal cancer is one of the clearest examples of biomarker-driven care in CRC. This trial reflects the shift toward tailoring treatment based on tumor biology. 
Patient Tip: If your tumor is dMMR or MSI-H, ask whether immunotherapy-based trials may be available before surgery. 
ClinicalTrials.gov: NCT04751370 

3. COMMIT Study — First-Line Immunotherapy Strategy in Metastatic dMMR/MSI-H Colorectal Cancer 
Biomarker Focus: dMMR / MSI-H 
Phase / Sites: Phase III / national multicenter trial 
Stage: Metastatic colorectal cancer 
Recruitment Status: Active, not recruiting 
What it’s studying: COMMIT is testing atezolizumab-based first-line treatment strategies, including chemotherapy/bevacizumab-containing approaches, in metastatic dMMR CRC. 
Why it matters: Although immunotherapy is already important in dMMR/MSI-H CRC, not all patients have durable benefit. COMMIT is trying to refine the best first-line approach for this population. 
Patient Tip: If you have metastatic dMMR/MSI-H CRC and are starting treatment, ask whether a first-line immunotherapy trial is an option. 
ClinicalTrials.gov: NCT02997228 

4. ERAS-007 Combination Trial in Advanced Gastrointestinal Malignancies, Including Colorectal Cancer 
Biomarker Focus: MAPK pathway / BRAF and RAS pathway signaling 
Phase / Sites: Phase Ib/II / Multicenter, including U.S. sites 
Stage: Advanced gastrointestinal malignancies, including metastatic CRC 
Recruitment Status: Completed 
What it’s studying: This study is evaluating ERAS-007, an ERK inhibitor, in combination regimens designed to interrupt downstream MAPK signaling in GI cancers, including CRC. 
Why it matters: Many CRC tumors are driven by pathway alterations that remain difficult to target directly. ERAS-007 reflects a newer strategy aimed at blocking downstream signaling to improve outcomes. 
Patient Tip: If your cancer has a BRAF or RAS-pathway alteration, ask whether downstream pathway-targeting trials may be appropriate. 
ClinicalTrials.gov: NCT05039177 

5. Nous-209 Vaccine Prevention Study in Lynch Syndrome 
Biomarker Focus: Lynch syndrome / mismatch repair deficiency risk 
Phase / Sites: Phase Ib/II / U.S.-based prevention study 
Stage: High-risk individuals with Lynch syndrome 
Recruitment Status: Active, not recruiting 
What it’s studying: This study is evaluating the Nous-209 vaccine strategy for cancer prevention in Lynch syndrome carriers at elevated risk for colon and other Lynch-associated cancers. 
Why it matters: This is a prevention-focused trial rather than a treatment trial, but it is highly relevant to colorectal cancer because it aims to reduce future cancer risk in a well-defined high-risk population. 
Patient Tip: If you or your family members have Lynch syndrome, ask whether prevention studies or surveillance-focused research may be appropriate. 
ClinicalTrials.gov: NCT05078866 

March 2026

1. ARPA-H ADAPT Oncology Platform – Colorectal Cohort 

Biomarker Focus: Real-time biomarker integration and adaptive trial infrastructure 
Phase / Sites: Early research initiative / United States 
Stage: Colorectal cancer (see eligibility criteria in protocol) 
Recruitment Status: Not yet recruiting 
What it’s studying: This ARPA-H supported initiative is part of the ADAPT oncology platform, designed to modernize how cancer clinical trials are conducted. The platform integrates advanced biomarker monitoring, coordinated data systems, and adaptive treatment strategies to accelerate therapeutic development in CRC and other cancers. 
Why it matters: Rather than testing a single drug, this national investment focuses on transforming the clinical trial system itself — potentially speeding up how promising treatments move from concept to clinic. 
Patient Tip: Even if enrollment hasn’t begun, ask your care team about upcoming federally funded research programs that may open new opportunities. 
ClinicalTrials.gov: NCT07318389

2. Molecularly Guided Therapy Based on Tumor Genetics: NCI-MATCH 

Biomarker Focus: Actionable genetic mutations 
Phase / Sites: Phase 2 / Nationwide (NCI-sponsored) 
Stage: Advanced solid tumors, including colorectal cancer 
Recruitment Status: Active, not recruiting 
What it’s studying: NCI-MATCH assigns treatment based on specific genetic mutations found in a tumor rather than the cancer’s location in the body. Patients with colorectal cancer whose tumors harbor actionable mutations may be matched to targeted therapies designed for those alterations. 
Why it matters: This national precision-medicine trial helped redefine how we think about treatment selection. Instead of a one-size-fits-all approach, MATCH reflects a shift toward therapy guided by tumor biology. 
Patient Tip: If you’ve had comprehensive genomic testing, ask whether your tumor’s mutations may qualify you for a MATCH sub-study. 
ClinicalTrials.gov: NCT02465060

3. COBRA Trial: ctDNA-Guided Predictor in Stage IIA 

Biomarker Focus: Circulating tumor DNA (ctDNA) 
Phase / Sites: Phase 2/3 / U.S. cooperative groups 
Stage: Stage II colon cancer 
Recruitment Status: Active 
What it’s studying: The COBRA study evaluates whether ctDNA testing after surgery can identify patients who truly need chemotherapy and who may safely avoid it. 
Why it matters: This study reflects the growing role of blood-based biomarkers in guiding adjuvant therapy, with the goal of reducing overtreatment while maintaining excellent outcomes. 
Patient Tip: If you have stage II colon cancer, ask whether ctDNA testing is appropriate for you and whether participation in a biomarker-guided trial is an option. 
ClinicalTrials.gov: NCT04068103

4. SWOG S2107: Immunotherapy Strategies in MSS Metastatic CRC 

Biomarker Focus: Microsatellite stable (MSS) and BRAF V600E mutation 
Phase / Sites: Phase 2 / National cooperative group (SWOG) 
Stage: Previously treated metastatic colorectal cancer 
Recruitment Status: Recruiting 
What it’s studying: This study is testing whether adding nivolumab (immunotherapy) to encorafenib + cetuximab improves outcomes in BRAF V600E/MSS metastatic CRC. 
Why it matters: Approximately 85–90% of colorectal cancers are MSS. Expanding immunotherapy strategies for this population remains one of the most urgent research priorities in CRC, and to a population that historically does not benefit from single-agent checkpoint inhibitors. 
Patient Tip: If you’ve been told your tumor is MSS and that immunotherapy alone is unlikely to work, ask whether combination immunotherapy trials are available at your treatment center. 
ClinicalTrials.gov: NCT04963283 

5. CIRCULATE-US (NRG-GI008) — ctDNA-Guided Adjuvant Strategy in Stage II/III 

Biomarker Focus: Circulating tumor DNA (ctDNA) 
Phase / Sites: Phase II/III / North America (NRG Oncology) 
Stage: Stage II and III (resected) colon cancer 
Recruitment Status: Recruiting 
What it’s studying: This randomized study evaluates whether post-surgical ctDNA testing can guide escalation or de-escalation of chemotherapy in patients with stage II or III colon cancer. Patients who test ctDNA-positive may receive intensified therapy, while those who test ctDNA-negative may receive less intensive treatment. 
Why it matters: ctDNA is emerging as a precision tool to detect minimal residual disease and personalize adjuvant therapy decisions. 
Patient Tip: If you’ve had surgery for stage II or III colon cancer, ask whether ctDNA testing or enrollment in a ctDNA-guided trial is appropriate for you. 
ClinicalTrials.gov: NCT05174169 

February 2026

1. BRAFTOVI® + Cetuximab + FOLFIRI — New Triplet Regimen for BRAF V600E mCRC

Biomarker Focus: BRAF V600E mutation
Phase / Sites: Phase 2 / Multinational (Pfizer-sponsored)
Stage: Metastatic (mCRC)
Recruitment Status: Active, not recruiting
What it’s studying: This study evaluates the combination of encorafenib + cetuximab + FOLFIRI in patients with previously treated, BRAF V600E-mutated metastatic CRC.
Findings: Results from ASCO GI 2026 show a significant increase in overall response rates (ORR) and progression-free survival compared to historical controls.
Why it matters: Offers a promising targeted therapy option earlier in the treatment journey for patients with BRAF-mutant CRC.
Patient Tip: If your tumor is BRAF V600E-positive and you’ve been previously treated, ask your care team about this combination.
ClinicalTrials.gov: NCT04607421

2. CIRCULATE-North America (NRG-GI008) — ctDNA-Guided Adjuvant Therapy in Stage II/III CRC

Biomarker Focus: Circulating tumor DNA (ctDNA)
Phase / Sites: Phase II/III / North America (NRG Oncology)
Stage: Stage II and III (resected)
Recruitment Status: Recruiting
What it’s studying: This randomized trial evaluates whether ctDNA testing after surgery can guide the need for adjuvant chemotherapy in patients with stage II or III colon cancer. Patients with detectable ctDNA may receive intensified treatment, while ctDNA-negative patients may avoid unnecessary chemotherapy.
Presented: ASCO GI 2026
Why it matters: ctDNA is emerging as a precision tool for assessing minimal residual disease (MRD). This trial could help patients avoid overtreatment—or identify recurrence risk earlier.
Patient Tip: If you’ve had surgery for stage II or III colon cancer, ask if ctDNA testing might inform your follow-up care plan.
ClinicalTrials.gov: ASCO Abstract: NRG-GI008

3. KEYNOTE-975 Subanalysis — Pembrolizumab in dMMR/MSI-H mCRC

Biomarker Focus: dMMR / MSI-H
Phase / Sites: Phase 3 / Global
Stage: Metastatic
Recruitment Status: Ongoing
What it’s studying: Examining the efficacy of pembrolizumab as a first-line treatment for dMMR/MSI-H metastatic CRC.
Findings: Durable responses reported in previously untreated patients, including those with comorbidities and older age groups.
Why it matters: Validates immunotherapy as a frontline option in dMMR CRC—not just for ideal candidates.
Patient Tip: If your tumor is MSI-H or dMMR, ask if you qualify for first-line immunotherapy.
ClinicalTrials.gov: NCT04003636

4. BEACON-Lite Cohort A — Real-World Evaluation of Triplet Therapy in BRAF CRC

Biomarker Focus: BRAF V600E mutation
Phase / Sites: Phase 2 / Expanded access
Stage: Metastatic
Recruitment Status: Closed to new participants
What it’s studying: A cohort evaluating encorafenib + cetuximab + chemotherapy in patients not eligible for the original BEACON trial.
Findings: Preliminary real-world data shows efficacy in older patients and those with comorbidities.
Why it matters: Supports more inclusive criteria for accessing promising triplet regimens.
Patient Tip: If you were previously excluded from BRAF-targeted trials, ask if real-world data may now support this approach.
ClinicalTrials.gov: NCT02928224

January 2026

1. BREAKWATER Trial — Triplet Therapy Sets New Standard for BRAF V600E mCRC

Biomarker Focus: BRAF V600E mutation
Phase / Sites: Phase 3 / Multi-national
Stage: Stage IV (metastatic)
Recruitment Status: Completed (Phase 3)
What it’s studying: Encorafenib + cetuximab + FOLFIRI vs chemotherapy in first-line mCRC
Findings: PFS nearly doubled (12.8 vs 7.1 months); OS improved to 30.3 vs 15.1 months
Why it matters: A new triplet could replace chemo as the standard for BRAF-mutated mCRC
Patient Tip: If you have BRAF V600E-mutant CRC and are starting first-line treatment, ask whether this triplet regimen is being considered.
ClinicalTrials.gov: N/A

2. ATOMIC Trial — Atezolizumab + Chemo in Stage III dMMR CRC

Biomarker Focus: Mismatch repair deficiency (dMMR / MSI-H)
Phase / Sites: Phase 3 / Multi-center
Stage: Stage III (resected)
Recruitment Status: Completed
What it’s studying: mFOLFOX6 with or without atezolizumab after surgery in stage III colon cancer
Findings: 3-year disease-free survival improved to 86.4% vs 76.6%
Why it matters: May change adjuvant therapy for early-stage dMMR CRC
Patient Tip: If your tumor is MSI-H/dMMR and you’re receiving adjuvant chemo, ask whether immunotherapy was considered or studied in your care setting.
ClinicalTrials.gov: NCT02912559

3. IVX037 + Sintilimab in MSS CRC — RNA Virus Therapy for IO-Resistant Tumors

Biomarker Focus: Microsatellite stable (MSS), KRAS mutations
Phase / Sites: Phase 1 / Single site (expansion)
Stage: Stage IV (refractory)
Recruitment Status: Expansion underway (Phase 1a complete)
What it’s studying: A bio-selected, receptor-targeted oncolytic RNA virus (IVX037) injected into tumors, combined with anti-PD-1 sintilimab
Findings: Disease control in patients with MSS and KRAS G12D CRC; early immune activation observed
Why it matters: One of the first intratumoral viral therapies showing benefit in MSS CRC: a population typically unresponsive to immunotherapy
Patient Tip: If your tumor is MSS and you’ve exhausted chemo options, ask your care team about clinical trials exploring novel immunotherapy combinations or virus-based therapies.
ClinicalTrials.gov: N/A

4. DYNAMIC-III Trial — ctDNA-Guided Escalation in Stage III CRC

Biomarker Focus: Circulating tumor DNA (ctDNA)
Phase / Sites: Phase 2 / Australia
Stage: Stage III (resected)
Recruitment Status: Completed
What it’s studying: Use of post-surgical ctDNA to guide chemotherapy intensity
Findings: Escalation based on ctDNA positivity improved outcomes; negative ctDNA patients avoided unnecessary chemo
Why it matters: Further validates ctDNA as a tool for adjuvant therapy decisions
Patient Tip: If you’ve had surgery for stage III CRC, ask if ctDNA testing could help tailor your chemotherapy plan.
ClinicalTrials.gov: NCT03803553

5. Tumor-Agnostic ADC Use in CRC – Real-World Data on KRAS G12C and HER2+ Subtypes
Biomarker Focus: KRAS G12C, HER2, and ADC-responsive profiles
Phase / Sites: Retrospective / Multiple centers
Stage: Stage IV (refractory)
Recruitment Status: Retrospective analysis of real-world patients (not an interventional trial)
What it’s studying: Outcomes among CRC patients treated with tumor-agnostic antibody-drug conjugates (ADCs) in third-line or later settings
Findings: HER2+ and KRAS G12C patients experienced stable disease or prolonged progression-free survival with investigational ADCs
Why it matters: Highlights the transition of novel ADCs from trials to practice and underscores the importance of biomarker matching in refractory mCRC
Patient Tip: If you’ve already tried standard treatments, ask your provider about biomarker testing for targets like HER2 or KRAS G12C, which may open access to novel ADC-based strategies through expanded access or real-world use.
ClinicalTrials.gov: N/A

The post On Our Radar: September 2026 Clinical Trials Roundup appeared first on Fight Colorectal Cancer.

About Call-on Congress 2027 

What is Call-on Congress? 

Call-on Congress is Fight CRC’s signature annual federal advocacy event, where advocates from across the country travel to Washington, D.C. to meet with their Members of Congress and push for policies that support colorectal cancer research, screening, and care. 

When and where is Call-on Congress 2027? 

Call-on Congress 2027 runs February 28 – March 2, 2027, at the Hilton National Landing in Arlington, VA. 

What’s new this year? 

Seats are limited at Call-on Congress 2027, so we’ve added a new application process this year. Applications are first-come, first-served within each state, so apply early to guarantee your spot.   

The Global Early Onset Colorectal Cancer (GEOCRC) Think Tank Global Collaborative is also happening at the same time, a separate event that brings together global research leadership. You’ll hear directly from Think Tank participants at Call-on Congress and see how their research connects to the policy asks you’ll bring to the Hill. 

What is the GEOCRC Think Tank Global Collaborative, and why does it matter to me as an advocate? 

 The GEOCRC Think Tank Global Collaborative brings together researchers, clinicians, and advocates from around the world to align global partners in the fight against early-onset colorectal cancer. Together, this international community is building the evidence base needed to understand and reverse the alarming rise of colorectal cancer in younger adults worldwide. As an advocate, you’ll see how the research priorities you’re asking Congress to fund connect to a larger, global research effort, giving your Hill meetings a stronger, evidence-backed story to tell. 

Registration & Eligibility 

Who can register? 

Any colorectal cancer advocate is welcome to apply. Because space is limited, registration is a structured first-come, first-served application. Applications open on October 1 and close on November 18.  

Is there a cap on attendance? 

Yes. Call-on Congress 2027 is capped at 175 attendees. Registration includes state-level caps so we can guarantee advocate voices from across the country are represented on the Hill. 

Why is there a cap, and why do states have limits? 

The cap and state limits help us guarantee a full room of advocates from as many states and districts as possible, rather than an uneven mix. If your state has reached its cap, you’ll go on the waitlist and will be notified if a spot opens up or if extra spots in your state become available due to lower applicant numbers in other states. While you wait, we will also help you find another way to take action in your own community (see “What if I can’t attend in person?” below). 

Spots can open up as the process moves along, so if your state is full and you end up on the waitlist, don’t count yourself out. Stay tuned; we’ll notify you if a spot becomes available. 

When does registration open and close? 

Registration opens October 1^st and closes November 18^th. We recommend applying early to make sure you get a spot at Call-on Congress. 

How do I apply?

More info on application coming soon. Stay tuned!

Is there a cost to apply and register? 

There is no cost to apply to attend Call-on Congress but applicants who are selected will be required to pay a $100 registration fee to complete the registration process. This fee helps support meals, programming, and transportation to Capitol Hill from the hotel on March 2^nd.  

Will I know if I got in before I have to make travel plans? 

Yes, all applicants will be notified whether they are on the registration list or waitlist by December 1^st. We recommend waiting to create traveling plans until after this point.   

Where will I stay at Call-on Congress? 

A room block will be available for attendees to book at the Hilton National Landing in Arlington, VA at a rate of $199 per night.  

Scholarships & Financial Support 

Is financial support available? 

Yes. Fight CRC offers a limited number of scholarships to help cover travel and attendance costs. Scholarships are meant to open the door for advocates who can’t otherwise attend, so don’t let cost hold you back from applying. Previous Fight CRC scholarship recipients are eligible to apply again.  

When will I hear back about a scholarship? 

Scholarship decisions will be shared on December 1, at the same time as application acceptance notifications. If you’re accepted, you’ll receive your scholarship information along with your acceptance, so you’ll have everything you need to make your travel plans with confidence. 

What does a scholarship cover? 

Scholarships are awarded based on need and availability, and can include any combination of the following: 

• Reduced registration: $25 

• Hotel: 2 nights covered at the event hotel 

• Travel stipend: up to $500 

Scholarships will not include all three. If you’re awarded a scholarship, your notification will explain exactly what is covered. 

Can’t Attend in Person? 

What if I can’t travel to D.C.? 

Don’t let distance stop you. This year we’re offering a community-based virtual advocacy option for advocates who can’t make it to D.C. in person, and it’s just as powerful. Request a meeting with your Members of Congress at their local district office, or connect virtually, and bring the same passion, the same story, and the same impact right to your own community. 

Below is more on how to get involved from home. 

How can I advocate from home? 

Call-on Congress is powerful, but it’s not the only way to make your voice heard. March From Home lets you take the same kind of action from wherever you are. 

Here’s how it works: March From Home kicks off in January, carries through our March Awareness push, and carries through the spring. You can send your story to the Hill, request a governor’s proclamation, get a flag kit, sign up EARLY as a Prevention Champion, or book a meeting with your member of Congress at their local district office. 

Stay tuned for more information on how to participate in March from Home! 

Preparing to Attend 

Do I need experience to attend? 

No. Call-on Congress welcomes both first-time and returning advocates. We offer advocacy workshops in January and February to help you prepare, covering the CRC policy priorities, how to tell your story effectively, and what to expect from a Hill meeting. All advocates will also be assigned a Regional Leader as a mentor before Call-on Congress. Fight CRC Regional Leaders are experienced advocates who can help prepare all Call-on Congress attendees to advocate in Washington DC in March, and back home in their communities for the rest of the year.  

What should I do after Call-on Congress ends? 

Watch for a post-event debrief and follow-up guide. We’re introducing a structured follow-up process this year to help you track responses from the offices you met with and stay engaged with your Members of Congress long after you leave DC. 

But the work doesn’t stop at follow-up emails. Your Hill Day meetings are the start of a relationship, not the end of one. Here are a few ways to keep the momentum going: 

• Follow up with your offices. Send a thank-you, share any resources you promised, and keep track of commitments made so you can hold them accountable. 

• Bring the ask home. Invite your Member of Congress to a local event, host a district meeting, or plan a community event that keeps CRC advocacy visible in your area. 

• Start planning for August recess. Members are back in their districts over the summer, which means it’s prime time for district meetings, town halls, and local events. Start thinking now about how you’ll show up when they’re home. 

• Stay plugged in. Join our Community of Champions, connect with your Regional Leader, and watch for opportunities to take action throughout the year. 

• Tell your story again. One meeting is powerful, but a Member of Congress hearing from you (and others) again and again is what actually moves the needle. 

Call-on Congress is a launchpad, not a finish line. Year-round advocacy is what turns a good meeting into real change. 

Key Dates 

The post Call-on Congress 2027: Registration FAQ  appeared first on Fight Colorectal Cancer.

Lancet Gastroenterol Hepatol. 2026 Sep 3:S2468-1253(26)00187-1. doi: 10.1016/S2468-1253(26)00187-1. Online ahead of print.

ABSTRACT

BACKGROUND: Colorectal cancer can arise from an inherited genetic background, but the diagnostic yield of multigene germline panel testing in patients diagnosed with colorectal cancer remains uncertain. The aim of this study was to quantify such yield.

METHODS: In this systematic review and meta-analysis, we searched PubMed (MEDLINE), Embase, Scopus, and the Cochrane Central Register of Controlled Trials from database inception to Aug 2, 2025, for studies published in English reporting the results of germline multigene panel testing of at least five genes using next-generation sequencing in unselected patients with colorectal cancer. Eligible study designs included cross-sectional and cohort studies, and clinic-based series in which all consecutive patients with colorectal cancer were offered multigene panel testing. Two independent reviewers, masked from each other’s decisions, screened records and extracted summary data and individual participant data, with conflicts resolved by a third reviewer. Risk of bias was assessed using the Newcastle-Ottawa Scale. The primary outcome was the person-level prevalence (diagnostic rate) of at least one pathogenic or likely pathogenic variant in cancer predisposition genes. Analyses were stratified by age at colorectal cancer diagnosis and gene penetrance. Random-effects meta-analyses estimated pooled prevalence. Heterogeneity was quantified using the I² statistic. Meta-regression evaluated the effect of age at colorectal cancer diagnosis, panel size, family history, and publication year on diagnostic rates. This study was registered in PROSPERO, CRD42025649177.

FINDINGS: Of 2707 records identified, 1682 duplicates were removed and screening excluded a further 985 records. 40 articles underwent full-text review, of which 21 met eligibility criteria and were included (ten [48%] at low, nine [43%] at moderate, and two [10%] at high risk of bias). Across 6925 individuals with colorectal cancer, the pooled rate of any pathogenic or likely pathogenic variant was 15·2% (95% CI 12·8-18·1; 1061/6925; I²=84·1%; k=12), with high-penetrance variants identified in 7·9% (5·9-10·5; 551/6909; I²=88·4%; k=11) and high-penetrance colorectal cancer predisposition variants in 5·4% (3·5-8·6; 408/6909; I²=93·4%; k=11). In early-onset colorectal cancer (age at diagnosis <50 years), yields were 17·7% (15·0-20·7; 1113/7444; I²=85·7%; k=16) for any pathogenic or likely pathogenic variant, 14·2% (11·7-17·3; 917/7409; I²=85·7%; k=15) for high-penetrance variants, and 12·2% (9·5-15·5; 788/7409; I²=89·5%; k=15) for high-penetrance colorectal cancer predisposition variants. In late-onset colorectal cancer (age at diagnosis ≥50 years), yields were 13·0% (10·8-15·7; 711/5243; I²=73·3%; k=11) for all variants, 6·5% (4·4-9·5; 349/5227; I²=86·4%; k=10) for high-penetrance variants, and 3·8% (2·0-7·5; 234/5227; I²=90·3%; k=10) for high-penetrance colorectal cancer predisposition variants. In meta-regression analyses, panel size and publication year did not affect yields. A higher prevalence of first-degree family history of colorectal cancer correlated with increased overall and colorectal cancer-specific variant yields, but not with non-colorectal variant yields. There was a progressive decline in yield with increasing age at colorectal cancer diagnosis, although the yield for high-penetrance variants remained greater than 5% up to age 67 years (95% CI 59-75).

INTERPRETATION: The yield of multigene panel testing is considerable in unselected patients with colorectal cancer, even beyond early-onset disease. The yield of high-penetrance germline variants remains above recognised testing thresholds up to age 67 years, providing a benchmark of universal testing for further study.

FUNDING: Italian Ministry of University, EU-Next Generation EU, and National Cancer Institute.

PMID:42692037 | DOI:10.1016/S2468-1253(26)00187-1

The post Germline multigene panel testing for colorectal cancer: a systematic review and meta-analysis appeared first on Fight Colorectal Cancer.

J Immunother Cancer. 2026 Sep 2;14(9):e015414. doi: 10.1136/jitc-2026-015414.

ABSTRACT

BACKGROUND: Immune checkpoint inhibitors (ICIs) have limited efficacy in proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC). However, selected patients with specific metastatic patterns may derive benefit.

METHODS: Patients with chemorefractory pMMR/MSS mCRC treated with ICI-based regimens were retrospectively identified. A comparison cohort treated with trifluridine/tipiracil±bevacizumab, regorafenib, or fruquintinib as standard of care (SOC) was generated through 1:1 propensity score matching by age, sex, Eastern Cooperative Oncology Group performance status (ECOG PS), liver metastases (present/absent), and RAS/BRAF status. Overall survival (OS) was compared using Cox regression.

RESULTS: A total of 354 patients treated with ICIs and 354 treated with SOC were matched. Median age was 55 years, 52% male, 32% ECOG PS 0, 30% right-sided, and 69% RAS mutated in both groups, while 61% and 60% had liver metastases, respectively. Median OS (mOS) was 10.8 months with ICIs and 9.0 months with SOC (HR 0.76, 95% CI 0.64 to 0.92, p=0.004). In patients without liver metastases, mOS was longer with ICIs than SOC (19.1 vs 13.2 months, HR 0.59, 95% CI 0.43 to 0.80, p<0.001), whereas outcomes were similar in patients with liver metastases (6.4 vs 6.5 months, p=0.303). In univariable analyses, age, sex, primary tumor site, and RAS/BRAF status were not associated with OS. Treatment with ICIs, absence of liver metastases, one prior line of therapy, less than three metastatic sites, and ECOG PS 0 were associated with the most favorable outcomes in univariable and multivariable models.

CONCLUSIONS: In chemorefractory pMMR/MSS mCRC without liver metastases, ICI-based regimens yielded longer OS than SOC. Further investigation of ICIs in this patient population is warranted.

PMID:42686374 | DOI:10.1136/jitc-2026-015414

The post Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients appeared first on Fight Colorectal Cancer.

Am J Gastroenterol. 2026 Sep 1;121(9):2086-2120. doi: 10.14309/ajg.0000000000004105.

ABSTRACT

The hereditary adenomatous colorectal polyposis syndromes are incurable, systemic, cancer risk predisposition syndromes with substantial morbidity and mortality. They differ in their mode of inheritance, age at disease onset, phenotypic expression, and cancer risk. The most common cancer risks involve the gastrointestinal tract including the colon, rectum, duodenum, ampulla, and stomach. Identifying these syndromes through personal and family history risk assessment and germline genetic testing, along with timely surgical and endoscopic management, can reduce cancer incidence and mortality. These guidelines use the Grading of Recommendations, Assessment, Development, and Evaluation methodology to provide clinical guidance on the selection of individuals who should undergo a risk assessment for a hereditary adenomatous colorectal polyposis syndrome, modality and timing of germline genetic testing, cancer risk mitigation through endoscopic and surgical interventions, and the role of chemoprevention. This document reviews the approach to genetic testing in patients with phenotypic colorectal polyposis and the impact of presymptomatic diagnosis in families with a known familial germline pathogenic variant or clinical features suggestive of a hereditary adenomatous polyposis syndrome. Management strategies for patients based on genetic test results or without genetic testing are provided. We also review colorectal and extracolonic phenotypic benign and malignant manifestations of the known hereditary syndromes with a focus on the 2 most common hereditary colorectal polyposis syndromes: familial adenomatous polyposis and MUTYH-associated polyposis. The document concludes with recommendations on polyposis and cancer risk mitigation strategies and highlights updates to management since the previous guideline was published.

PMID:42683623 | DOI:10.14309/ajg.0000000000004105

The post ACG Clinical Guideline: Diagnosis and Management of Adenomatous Colorectal Polyposis Syndromes appeared first on Fight Colorectal Cancer.

Frequently Asked Questions from the Fight CRC Webinar 

Starting treatment for metastatic colorectal cancer raises a lot of questions — about biomarkers, treatment choices, and whether clinical trials are right for you. This FAQ captures key takeaways from Fight CRC’s webinar with answers from our expert panelists. 

Featuring: 

• Dr. Christopher Lieu, Professor of Medicine and Associate Director for Clinical Research, University of Colorado School of Medicine 

• Bill Thach, Fight CRC Research Advocate and colorectal cancer patient 

What is first-line treatment for metastatic colorectal cancer? 

First-line treatment is the first treatment you receive after a metastatic diagnosis. What your care team recommends will depend on your overall health, your tumor’s biomarker profile, your goals, and whether surgery might be an option. 

One of the most important early conversations to have with your oncologist: What is the goal of treatment? Is the aim to shrink the cancer? To keep it stable? Getting aligned on that shapes everything that follows. 

What questions should I ask at my first oncology appointment? 

Dr. Lieu recommends starting with these five: 

1. What stage is my cancer? 

2. What treatments are available for me? 

3. What are the goals of those treatments? 

4. Has my tumor been tested for biomarkers? 

5. Are clinical trials available for my cancer? 

What is biomarker testing, and does it matter if I already started treatment? 

Biomarker testing looks for specific changes in your tumor’s genes that tell your care team how your cancer behaves and which treatments are more likely to work for you. It goes by several names: tumor testing, molecular testing, mutation testing, or next-generation sequencing (NGS). 

If you are not sure whether you have been tested, ask now. If you are being treated in the metastatic setting, it is absolutely worth bringing up. Dr. Lieu recommends two direct questions: 

1. Has my tumor been tested for biomarkers? 

2. If no, why not? If yes, how do those results impact my treatment now and in the future? 

What is the difference between biomarker testing and genetic testing? 

They are often confused, but they are different. Biomarker testing looks at mutations within your cancer cells specifically — changes that happened in the tumor, not ones you were born with. Genetic testing looks at inherited DNA and can reveal hereditary risk factors like Lynch syndrome, which has implications for family members as well. Both can be important. Ask your care team whether you have had each. 

Should I be thinking about clinical trials from the start? 

Yes. Clinical trials are not a last resort — they are a legitimate treatment option at every stage, including first-line. Dr. Lieu’s recommendation: ask your oncologist at your first appointment whether any trials are available for your specific biomarker profile. 

If you are told to start chemotherapy first, ask two follow-up questions before you begin: Are there any first-line trials available for me right now? And would one cycle of treatment disqualify me? Many trials allow one prior cycle, so starting standard therapy does not always close the door — but it is important to ask before, not after. 

I don’t qualify for the trial I found. What now? 

Do not stop there. Ask whether other trials exist, look beyond your current institution, and consider reaching out directly to the trial’s contact on ClinicalTrials.gov. As Bill puts it: “There is always a trial. You just have to do some work to get there.” 

Two tools that can help: ClinicalTrials.gov is the full database of open trials. ChatCRC (chatbot.fightcolorectalcancer.org) is Fight CRC’s AI-powered tool that lets you search in plain language — Dr. Lieu demonstrated that a simple prompt surfaced six relevant trials versus roughly 50 unfiltered results on ClinicalTrials.gov. 

What is it actually like to be on a clinical trial? 

The time commitment is one of the biggest things patients underestimate, especially in early cycles. But Bill also noted that the level of monitoring on a trial is often more intensive than standard care — your health is top of mind for that institution. 

Before enrolling, Bill recommends asking: What is the patient’s responsibility? What are the side effect profiles? And what does the time commitment actually look like week to week? 

What is the single most important piece of advice for a newly diagnosed patient? 

We asked both panelists. 

Bill: “Understand that you should be accountable for your own health. Once you do that, you will have the curiosity to find what options are out there for you.” 

Dr. Lieu: “Advocate for yourself, but bring people who will advocate for you — a friend, a family member, a patient advocate — because having backup in that room makes a real difference.” 

Fight CRC Resources and Next Steps 

Learn 

• Biomarker Testing Guide

• Clinical Trials Resources

Find Trials 

• ChatCRC

• ClinicalTrials.gov 

Connect 

• Community of Champions App

• Ambassador Program

Advocate 

• RATS Program  

• Call on Congress

Stay Informed 

• Subscribe to the Clinical Trials Newsletter 

Thank you to Our Sponsor

This webinar was supported by Pfizer. Fight CRC independently develops and curates all content. The information in this FAQ is for general educational purposes only and is not a substitute for professional medical advice. Please consult your care team about your individual situation.

The post Clinical Trials and First-Line Metastatic CRC: What Patients Should Know Before Starting Treatment  appeared first on Fight Colorectal Cancer.

Colorectal Cancer Equity Foundation, V Foundation for Cancer Research, and First Ascent Biomedical have joined a growing national coalition working to close gaps in colorectal cancer care

[Springfield, Missouri] Fight Colorectal Cancer (Fight CRC) today highlighted the expansion of its Colorectal Cancer Care Initiative (CRCCI), a national coalition focused on transforming screening, diagnosis, and treatment standards, which has welcomed three new endorsing organizations. The Colorectal Cancer Equity Foundation, V Foundation for Cancer Research, and First Ascent Biomedical have all signed on to lend their support to the initiative, which unites organizations around a shared set of benchmarks aimed at improving outcomes at every stage of the colorectal cancer care continuum, from screening and diagnosis through treatment and follow-up care.

The three organizations bring distinct strengths in community-based equity work, cancer research funding, and precision medicine to a coalition already spanning health systems, advocacy groups, employers, and medical associations nationwide.

“Closing the gaps in colorectal cancer care takes more than any one type of organization can do alone,” said Joya Delgado Harris, Director of CRCCI at Fight Colorectal Cancer. “These three organizations each bring something unique to this coalition, reflective of the all-hands-on-deck approach and commitment that colorectal cancer patients deserve.”

Colorectal Cancer Equity Foundation, which joined CRCCI this summer, works to close disparities in colorectal cancer outcomes among African-American men and other underserved populations, meeting people directly in their communities through education, screening access, and grassroots partnership.

V Foundation for Cancer Research, also an endorser since this summer, funds cancer research and scientists working to accelerate breakthroughs across the field. As a research funder rather than a direct care provider, its endorsement reflects how CRCCI’s goals resonate not only with those delivering care, but with those funding the discoveries meant to improve it.

First Ascent Biomedical, the coalition’s newest endorser, is a biotechnology company that tests hundreds of FDA-approved drugs against a patient’s own cancer cells to identify which treatments are most likely to work, helping clinicians make faster, more precise treatment decisions.

CRCCI includes endorsing organizations across health systems, pharmaceutical and diagnostics companies, nonprofit and patient advocacy groups, and medical associations. Endorsers are united around two CRCCI goals with measurable targets. Goal 1 focuses on timely screening for prevention and early detection, aiming for an 80% screening rate among average-risk patients and ensuring 80% of patients with an abnormal non-invasive test receive follow-up colonoscopy within 90 days. Goal 2 focuses on accurate diagnosis and timely treatment initiation, with targets of 80% of CRC patients receiving biomarker testing per NCCN Guidelines®, 80% receiving germline genetic testing at diagnosis, and 80% initiating treatment within six weeks of diagnosis.

To learn more about CRCCI or to inquire about becoming an endorsing organization, visit fightcolorectalcancer.org or contact Joya Delgado Harris at joya@fightcrc.org.

About Fight Colorectal Cancer

Fight CRC is the leading colorectal cancer advocacy organization offering patient support, screening guidance, research updates, and ways to take action against colon and rectal cancer.

About the Colorectal Cancer Care Initiative

The CRCCI is a national coalition of patient advocates, physicians, public health champions and healthcare leaders uniting around data-driven goals to transform colorectal cancer (CRC) screening, diagnosis, and treatment. Learn how your organization can join the initiative and advance our shared mission.

Media Contact:
Name: Joya Delgado Harris
Email: joya@fightcrc.org.

The post Fight Colorectal Cancer Coalition Grows with Three New Endorsing Organizations appeared first on Fight Colorectal Cancer.

Here’s the short version: 

• The government pays $50,000 to $100,000 to people who got certain cancers after being exposed to radiation from U.S. nuclear weapons work. 
• Colon cancer is on the list. (More on colon vs. rectal cancer below—this part matters.) 
• You don’t have to prove radiation caused your cancer. You just have to show you had a covered cancer and lived or worked in the right place at the right time. 
• It’s free to apply, and families of people who have passed away can still file. For more info, please visit: https://www.justice.gov/civil/reca
• The deadline is December 31, 2027. 

Let’s walk through whether you qualify.

First: Does Your Diagnosis Count?

This is the most important question, so let’s be clear and honest about it. 

Colon cancer IS covered. If you were diagnosed with colon cancer, your diagnosis is on RECA’s list of covered diseases (for the categories described below). 

About rectal cancer: RECA’s official list names “colon” cancer. It does not separately list “rectal” cancer. “Colorectal cancer” is an umbrella term that includes both colon and rectal cancers—but the DOJ program language specifically says colon. 

What this means for you: If your diagnosis was colon cancer, you’re on solid ground. If your diagnosis was rectal cancer specifically, it’s not clearly named on the list—but it’s still worth calling the RECA Program (1-800-729-7327) to ask about your exact diagnosis before assuming you don’t qualify. Bring your medical records, which will state the precise diagnosis. Don’t rule yourself out based on this blog alone.

Second: Did You Live or Work in a Covered Area? 

If you had colon cancer, the next question is where you lived, worked, or went to school—and when. There are two situations most likely to apply to colorectal cancer survivors. 

Situation A: You lived near nuclear test fallout (“Downwinders”) 

You may qualify if you were physically present in one of these areas during a qualifying time: 

The areas: the states of Idaho, New Mexico, and Utah, plus these counties: 

• Arizona: Coconino, Yavapai, Navajo, Apache, Gila, and Mohave 
• Nevada: White Pine, Nye, Lander, Lincoln, Eureka, and parts of Clark County 

The timing (you need one of these): 

• Lived in New Mexico for 1 year between September 24, 1944, and November 6, 1962 
• Lived in any affected area for 1 year between January 21, 1951, and November 6, 1962 
• Lived in any affected area for the whole period of June 30 – July 31, 1962 

If you qualify: a one-time payment of $100,000. If the person has passed away, their survivors can share the payment. 

Situation B: You lived near Manhattan Project radioactive waste (new in 2025) 

This category was added in July 2025 and is especially important for people in the St. Louis, Missouri area. You may qualify if you lived, worked, or went to school in a covered ZIP code for at least 2 years after January 1, 1949. 

Covered Missouri ZIP codes (St. Louis area): 

63031, 63033, 63034, 63042, 63045, 63074, 63114, 63135, 63138, 63044, 63121, 63140, 63145, 63147, 63102, 63304, 63134, 63043, 63341, 63368, 63367 

(The program also covers certain ZIP codes in Tennessee, Kentucky, and Alaska—see the DOJ site for those.) 

If you qualify: 

• If you’re living when you file: the greater of $50,000, or your documented out-of-pocket medical costs from the illness that insurance didn’t cover. 
• If the person has passed away: $25,000 to their surviving spouse (or split among their children if there’s no spouse). 

How Much Could You Get? 

How to Apply (Two Easy Ways) 

You can apply online or by mail. It’s free. You cannot apply by email. 

The easy way: Apply online 

Go to the official portal and follow the steps: RECA Claim Portal — reca.justice.gov 

You can upload photos or scans of your documents to speed things up. 

Or apply by mail 

Step 1 — Download the form that matches your situation: 

• Downwinder Claim Form (fallout areas) 
• Manhattan Project Waste Claim Form (St. Louis-area waste) 

Step 2 — Gather your documents. You’ll need: 

• Proof you lived or worked there during the right time (old leases, utility bills, school records, tax records, employment records, etc.) 
• Medical records showing your colon cancer diagnosis 
• A photo ID or other identification listed on the form 

For mailed claims, send original or certified copies. 

Step 3 — Mail it to:

Keep a copy of everything you send. 

Questions Colorectal Cancer Survivors Ask 

I had colon cancer. Does that really count? 

Yes—colon cancer is on RECA’s list of covered diseases for the categories above. You’ll still need to show you lived or worked in a covered area during a qualifying period. 

My diagnosis was rectal cancer, not colon. Do I qualify? 

RECA’s official list names “colon” cancer and doesn’t separately list rectal cancer. That doesn’t automatically mean no—but it’s not clearly listed either. Call the RECA Program at 1-800-729-7327 and ask about your specific diagnosis before deciding. Have your pathology report handy. 

Do I have to prove radiation gave me cancer? 

No. That’s the whole point of RECA—you don’t have to prove what caused your cancer. You only show that you had a covered cancer and lived or worked in a covered area during the right time. 

My mom/dad/spouse had colon cancer but passed away. Can I still file? 

Yes. Surviving family members can file. The amount depends on the category (see the table above). 

How much does it cost to apply? 

Nothing. Filing directly with the DOJ is free. Be careful of companies that charge big fees to file for you—you can do it yourself at no cost, and the RECA staff will help you over the phone. 

How long does it take to hear back? 

You’ll get an acknowledgment letter after you file. Because so many people are applying, it may take a while. Once you get your RECA Claim Number, use it in any future calls or letters. 

What if I’m not sure whether I qualify? 

Call the free RECA helpline: 1-800-729-7327, Monday–Friday, 9 a.m.–5 p.m. Eastern. It’s better to ask than to assume you don’t qualify. 

Is there a deadline? 

Yes—December 31, 2027. All claims must be filed by then. 

Where to Get Help 

• Official DOJ RECA website: justice.gov/civil/reca 

• Apply online: reca.justice.gov 

• Free RECA helpline: 1-800-729-7327 (Mon–Fri, 9 a.m.–5 p.m. ET) 

• Email the RECA Program: Civil.RECA@usdoj.gov (include your name and claim number) 

• Free medical screening (RESEP clinics): hrsa.gov radiation exposure 

Missouri residents — local help 

If you’re in Missouri, the office of U.S. Senator Josh Hawley has a RECA point of contact who can help answer questions about the program: 

The Bottom Line 

If you had colon cancer and lived, worked, or went to school in a covered area—especially the St. Louis region or a nuclear fallout state—it costs nothing to find out if you’re owed $50,000 to $100,000. Families of those who have passed away can file too. 

The deadline is December 31, 2027. Start at the official DOJ RECA website or call 1-800-729-7327 today.

This article is provided for education by Fight CRC and is not legal or medical advice. Only the U.S. Department of Justice decides who qualifies. Details are current as of the DOJ RECA page dated August 24, 2026, and may change—always confirm on the official DOJ website before filing. 

The post Did You Have Colon Cancer? You May Be Owed $50,000–$100,000 Through RECA  appeared first on Fight Colorectal Cancer.

Cancer. 2026 Sep 1;132(17):e70584. doi: 10.1002/cncr.70584.

ABSTRACT

BACKGROUND: Cancer statistics for Asian American and Native Hawaiian and Pacific Islander (NHPI) people are usually aggregated, masking substantial variation within this heterogeneous population. Herein, the American Cancer Society reports cancer incidence and survival for 8 Asian American and 3 NHPI ethnic groups.

METHODS: The authors used population-based cancer registry data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results program, for Asian American and NHPI ethnic groups from 2000 through 2022.

RESULTS: During 2018-2022, overall cancer incidence ranged from 218.3 per 100,000 Kampuchean people to 474.5 per 100,000 Native Hawaiian people, which was 1.5 times higher than the rate for the aggregated Asian American and NHPI population (307.3 per 100,000). High incidence among Native Hawaiian people is largely driven by the highest rates of female breast, colorectal, and prostate cancers, whereas infection-related cancers were highest among Asian American ethnic groups. For example, liver and stomach cancer incidence is highest among Vietnamese (22.2 per 100,000) and Korean people (17.8 per 100,000), respectively, both of which were nearly twice that in Native Hawaiian people (12.9 and 9.6 per 100,000, respectively). Native Hawaiian and Samoan women are twice and 3 times as likely, respectively, to be diagnosed with uterine corpus cancer as aggregated Asian American and NHPI women or White women. Five-year relative survival ranges from 42% in Laotians to 74% in Asian Indians/Pakistanis, with largest differences for colorectal (43% in Laotians to 72% in Asian Indians/Pakistanis) and prostate (63% in Kampucheans to 97% in Japanese) cancers.

CONCLUSIONS: Wide variation in cancer risk within the Asian American and NHPI population highlights the critical need for disaggregated data to effectively target cancer prevention and control interventions.

PMID:42658095 | DOI:10.1002/cncr.70584

The post Cancer statistics for Asian American, Native Hawaiian, and Pacific Islander people, 2026 appeared first on Fight Colorectal Cancer.

Nat Rev Cancer. 2026 Aug 26. doi: 10.1038/s41568-026-00965-5. Online ahead of print.

ABSTRACT

Early-onset colorectal cancer (EOCRC) among individuals under age 50 is increasing globally. Lifestyle factors such as obesity, metabolic comorbid conditions, poor diet and sedentary behaviours are linked to EOCRC, but critical gaps remain in identifying additional risk factors, with growing evidence for early-life and gut microbial-related exposures. In addition, how or when the risk factors act, individually or collectively, to initiate or promote colorectal cancer at much younger ages remains unknown. Compounding the complexity are the unique challenges of developing and implementing effective prevention strategies among younger populations. In this Roadmap, we review the progress and challenges of risk factor discovery for EOCRC, highlight opportunities for prevention and propose a transdisciplinary framework integrating population, mechanistic, behavioural and implementation sciences to accelerate causal risk factor discovery and translate insights into strategies to reverse the rising EOCRC burden. This framework, exemplified by emerging global initiatives including the Cancer Grand Challenges team PROSPECT, is broadly adaptable and intended to inspire collaborative efforts across the field. We also emphasize the critical role of patient perspectives and public engagement in shaping these efforts. With the urgency in risk factor discovery, scientists, the public and policymakers must unite to transform knowledge into life-saving solutions for future generations.

PMID:42649278 | DOI:10.1038/s41568-026-00965-5

The post Shaping the future of early-onset colorectal cancer prevention appeared first on Fight Colorectal Cancer.